Company Overview - Huajian Medical Holdings Limited was established on January 15, 2016, under the laws of the Cayman Islands, primarily engaged in investment holding [3] - The company operates three subsidiaries in Hong Kong, focusing on research, production, and sales of in vitro diagnostic medical instruments and consumables, with a workforce of over 700 employees [3] - Huajian Medical has become a leading professional company in the in vitro diagnostic industry in China, providing valuable products and services to the testing sector [3] Financial Performance - As of December 31, 2024, Huajian Medical achieved total revenue of 3.162 billion yuan, representing a year-on-year growth of 2.4% [2] - The net profit attributable to the parent company was 260 million yuan, with a year-on-year increase of 9.35% [2] - The gross profit margin stood at 23.75%, and the debt-to-asset ratio was 31.91% [2] Stock Performance - As of August 6, the stock price of Huajian Medical closed at 7.96 HKD per share, marking an increase of 38.43% with a trading volume of 8.6666 million shares and a turnover of 57.6121 million HKD [1] - Over the past month, the stock has seen a cumulative increase of 179.13%, and a year-to-date increase of 219.44%, outperforming the Hang Seng Index's growth of 24.14% [2] Valuation Metrics - Currently, there are no institutional investment ratings for Huajian Medical [3] - The company's price-to-earnings (P/E) ratio is 33.12, ranking 37th in the healthcare equipment and services industry, which has an average P/E ratio of -0.3 and a median of 1.39 [3] - Comparatively, other companies in the industry have P/E ratios such as Jingjiu Kangliao at 0.38, Juxing Medical Holdings at 0.44, and Yihui Group at 2.35 [3]

华检医疗控股有限公司于2016年01月15日根据开曼群岛法注册成立,其主要业务为投资控股。集团在中 国香港设有三家子公司,威士达医疗有限公司、中华检验国际有限公司及艾维德(中国)有限公司。三家子 公司在中国大陆各设有子公司或分公司,在全国各主要城市设有办事处。公司拥有超700名员工,主要从事 研发、生产、销售体外诊断的医疗仪器及耗材,业务遍布中国及中国香港。从1993年创立威士达医疗有 限公司,公司专注体外诊断业务,经过二十多年的发展,公司现已成为中国领先的体外诊断业务的专业公司, 为中国检验界提供超值产品及服务。 （以上内容为金融界基于公开消息，由程序或算法智能生成，不作为投资建议或交易依据。） 来源：金融界 截至8月4日收盘，华检医疗（01931.HK）报5.480港元，较上个交易日上涨20.7%，当日盘中最高价触 及5.500港元，创近一年新高。 资金流向方面，当日主力流入NaN万港元，流出NaN万港元，净流入805.45万港元。 ...

Company Overview - Huajian Medical Holdings Limited was established on January 15, 2016, under the laws of the Cayman Islands, primarily engaged in investment holding [3] - The company operates three subsidiaries in Hong Kong: Weida Medical Limited, China Inspection International Limited, and Avid (China) Limited, with additional subsidiaries or branches in major cities across mainland China [3] - Huajian Medical focuses on research, production, and sales of in vitro diagnostic medical instruments and consumables, employing over 700 staff [3] Financial Performance - As of December 31, 2024, Huajian Medical reported total revenue of 3.162 billion yuan, a year-on-year increase of 2.4% [2] - The net profit attributable to shareholders was 260 million yuan, reflecting a year-on-year growth of 9.35% [2] - The gross profit margin stood at 23.75%, while the debt-to-asset ratio was 31.91% [2] Stock Performance - As of July 15, the stock price of Huajian Medical closed at 2.28 HKD per share, marking a 12.87% increase with a trading volume of 445,000 shares and a turnover of 977,600 HKD [1] - Over the past month, the stock has experienced a cumulative decline of 10.62%, while year-to-date, it has risen by 12.22%, underperforming the Hang Seng Index, which has increased by 20.65% [2] Industry Valuation - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -3.18 times, with a median of 1.17 times [3] - Huajian Medical's P/E ratio is 11.65 times, ranking 21st in the industry [3] - Comparatively, other companies in the sector have varying P/E ratios, with Giant Medical Holdings at 0.28 times, Jingjiu Medical at 0.38 times, and others ranging up to 5.4 times [3] Important Events - A significant event is anticipated on July 14, 2025, where the company expects a decrease in mid-year performance, projecting a profit attributable to shareholders of approximately 33 million RMB, a decline of 73.6% year-on-year [4]